FOXO4 D-Retro-Inverso Peptide
Evidence Grade D — Primarily preclinical. 16 published studies, mostly animal models. 0 registered clinical trials.
FOXO4-DRI is a 46-amino-acid peptide designed to selectively kill senescent cells — damaged cells that accumulate with age and release inflammatory signals that harm surrounding tissue. It uses a mirror-image design that resists the body's enzymes. A single high-profile publication (in Cell, 2017) demonstrated effects in three mouse models. No human clinical trials have been conducted.
16 published studies: 7 human, 5 animal, 5 in-vitro, 3 reviews
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models.
The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
Research suggests FOXO4-DRI works by disrupting an interaction between two proteins (FOXO4 and p53) that keeps senescent cells alive. In normal cells, this interaction is absent, so the peptide has no effect. In senescent cells, blocking this interaction is proposed to release p53 to trigger cell self-destruction. This selective senolytic mechanism has been demonstrated in cell culture and mouse models in a single landmark publication.
Research suggests the original Cell publication includes rigorous controls, and independent groups have subsequently validated the mechanism in different disease contexts including osteoarthritis and radiation-induced fibrosis. A 2025 structural study provided molecular confirmation of how the peptide works. Active commercial development by a biotech company (Cleara Biotech) indicates industry interest. However, no human data of any kind exist. Manufacturing a 46-amino-acid all-D-amino-acid peptide to pharmaceutical standards is exceptionally complex and expensive, raising serious doubts about the quality of products from unregulated sources. Theoretical concerns about eliminating senescent cells that serve beneficial roles (wound healing, tumour suppression) remain unresolved.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
Afamelanotide is marketed as Scenesse (Clinuvel Pharmaceuticals, approved October 2019 in the US; previously approved in the EU in 2014). It is delivered as a bioresorbable subcutaneous implant administered every two months. Treatment is only available through a restricted distribution programme. In clinical trials, EPP patients on afamelanotide could spend significantly more time in direct sunlight without pain. EPP is a debilitating condition where even brief light exposure can cause hours of burning pain, and prior to Scenesse there was no approved treatment. Afamelanotide is related to the research compound Melanotan I, but is the only version that has undergone full regulatory approval for a specific medical condition.
